IBB vs XLV
iShares Biotechnology ETF vs Health Care Select Sector SPDR Fund
- • XLV has the lower expense ratio at 0.08% vs 0.44% for IBB.
- • XLV pays a higher dividend yield (1.38%).
Side-by-side metrics
| Metric | IBB | XLV |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.44% | 0.08% |
Dividend yield Trailing 12-month yield. | 0.16% | 1.38% |
AUM Assets under management — bigger funds are typically more liquid. | $11.50B | $49.10B |
YTD return | 30.22% | 23.16% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.60 | 0.41 |
P/E ratio | 25.48 | 30.63 |
Last price | $217.75 | $187.94 |
Inception | — | — |
Issuer | iShares | State Street |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
XLV top holdings
| LLY | Eli Lilly and Co | 16.88% |
| JNJ | Johnson & Johnson | 9.80% |
| ABBV | AbbVie Inc | 7.76% |
| MRK | Merck & Co Inc | 5.49% |
| UNH | UnitedHealth Group Inc | 5.44% |
| TMO | Thermo Fisher Scientific Inc | 3.84% |
| AMGN | Amgen Inc | 3.75% |
| GILD | Gilead Sciences Inc | 3.15% |
| ABT | Abbott Laboratories | 2.74% |
| PFE | Pfizer Inc | 2.59% |
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About XLV
XLV (Health Care Select Sector SPDR Fund) is S&P 500 health care sector. Managed by State Street, the fund carries $49.1B in assets under management, an expense ratio of 0.08%, a dividend yield of 1.38%. Its largest holding is Eli Lilly and Co (LLY), which represents 16.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.